8 results
This study will explore the safety, tolerability, PK, immunogenicity, PD, and preliminary efficacy of RO7428731, in participants with newly diagnosed and recurrent EGFRvIII-positive GBM.
• To evaluate the safety and tolerability of Runimotamab when administered as a single agent (Phase Ia) and in combination with trastuzumab (Phase Ib)• To determine the maximum tolerated dose (MTD), to identify the recommended phase II dose (RP2D),…
Primary Efficacy objective: The purpose of the study is to test the efficacy of the Neuspera Implantable SNS System for treatment of urinary urgency incontinence Primary safety objective: The primary safety objective of the study is to assess the…
The primary objective is to evaluate whether a switching strategy using adalimumab concentration (TDM) is superior to usual care in rheumatoid arthritis patients failing adalimumab treatment with regard to response rates. The secondary objectives…
The objective of this study is to obtain clinical performance (outcomes) data and survivorship for commercially available Zimmer Persona knee implants implanted in primary total knee arthroplasty.
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.
This single arm, multi-center, phase II study will determine the efficacy and safety of tisagenlecleucel in adult patients with FL who failed at least 2 prior systemic therapies, including an anti-CD20 antibody (e.g. rituximab) and an alkylating…
This Phase II, open-label, multicenter study, will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with R-CHOP in individuals with ctDNA high-risk DLBCL in the first-line setting. Specific objectives and…